Company intelligence / Profile preview

Calgent Biotechnology

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Calgent Biotechnology develops novel small molecule therapeutics targeting cancers—including colorectal and liver cancers—and inflammatory/immune diseases. Its lead asset CAL056 has Orphan Drug Designation for multiple myeloma and entered Phase I trials in the US after FDA IND approval in October 2020. Preclinical data show anti-tumor activity with low toxicity across several tumor types. The company leverages academic-industry collaborations from its roots as a Taipei Medical University spin-off to advance a pipeline of innovative drug candidates addressing unmet medical needs in oncology and immunology.

Therapeutic areas: OncologyImmunology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

5 assets

CAL056 mesylate

4 more assets in the full pipeline.

Partnerships

Precision medicine platform partnersuniversity-industry collaborations with Taipei Medical University.

Beyond the preview

Go deeper on Calgent Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calgent Biotechnology.